Vitamin K2 for Bone Health in Children With Nephrotic Syndrome Taking Steroids
Tests vitamin K2 on bone health in children with nephrotic syndrome on steroids.
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Apr 2025
- Planned end
- 30 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vitamin K 2
- Record updated
- 3 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with nephrotic syndrome who have taken steroid medicine (glucocorticoids) for more than 6 months. It studies whether vitamin K2 taken by mouth protects their bones.
- Age
- 1 Year to under 16 years
- Sex
- Boys and girls can join.
- Disease stage
- Nephrotic syndrome (a kidney condition that causes protein loss in the urine), treated with glucocorticoids for the first time.
- Earlier treatment
- Glucocorticoid treatment for the first time, started at 2 mg/kg/day prednisolone and slowly lowered. Must have been on glucocorticoids for more than 6 months.
- Biomarker or test result
- Vitamin D level of 30 ng/ml (75 nmol/L) or above.
Main reasons for not taking part
- Reduced kidney function.
- Not taking medicines or vitamin supplements as prescribed.
- Diseases that affect absorption of fat-soluble vitamins, such as gallbladder or bile duct disease, cystic fibrosis or celiac disease.
- History of vitamin K-related disorders, such as bleeding disorders or osteomalacia (soft bones), or a broken bone before the study.
- Nephrotic syndrome with a known genetic cause.
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Nephrotic patients under 16 years of age of both genders who were treated with GC for the first time. GC treatment was initiated at a dose of 2 mg/kg/day prednisolone with gradual dose reduction
- All patients have been on glucocorticoid therapy for more than 6 months. All patients have sufficient vitamin D level 30 ng/ml (75 nmol/L) or above
Who cannot take part
- Non-compliant patients on medications or vitamin supplements
- Diseases that affect fat-soluable vitamins absorption such as gallbladder or biliary disease, cystic fibrosis, celiac disease, etc
- History of vitamin K-related disorders as bleeding disorders, osteomalacia , etc
- History of bone fracture before the study
- Any nephrotic syndrome with identified genetic causes
- Patients with impaired kidney functions
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 16 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Long-term glucocorticoids therapy is associated with various complications, including decreased bone strength (Glucocorticoid-induced osteoporosis) and an increased risk of fracture.
Read full original descriptionShow less
Vitamin K2 has been recently deemed appreciable as a topic of research as it plays a pivotal role in maintenance of the bone strength, and it has been proved to have a positive impact on the bone metabolism.
This study examines the impact of oral vitamin K2 supplementation on bone metabolism in pediatric patients with nephrotic syndrome on long-term steroid therapy, offering valuable therapeutic insights
The 2 groups in the trial
- ControlNo study treatment, for comparison
30 Nephrotic patients of matched age and sex of the cases have been on Glucocorticoids for 6 months or more not receiving vitamin k2 supplements
- CaseExisting treatment, for comparison
30 Nephrotic patients of matched age and gender who have been on Glucocorticoids for 6 months or more, receiving vitamin k2 supplements for 24 weeks.
Treatment: Vitamin K 2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome
- Plain-language title
- Vitamin K2 for Bone Health in Children With Nephrotic Syndrome Taking SteroidsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07206537, who can take part
- Record updated
- 3 October 2025